BackAvalyn Pharma Common Stock Overview

Avalyn Pharma Common Stock Receivables

Track Avalyn Pharma Common Stock's receivables ($250K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$253000.00

Peer average / median

Loading

Avalyn Pharma Common Stock Receivables History

Loading

Avalyn Pharma Common Stock vs. peers: Receivables Comparison

Loading

Avalyn Pharma Common Stock Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Avalyn Pharma Common Stock (AVLN) FAQ

As of the most recent data (March 2026), AVLN shows a receivables of $250K. Scroll down for historical charts and peer comparison views.

Tracking AVLN's receivables over time shows whether Avalyn Pharma Common Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $250K Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Avalyn Pharma Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $250K) with ownership activity and broader fundamentals.

Avalyn Pharma Common Stock's receivables is $250K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.